Mads Krogsgaard Thomsen
Director/Board Member at BB BIOTECH AG
Profile
Currently, Mads Krogsgaard Thomsen occupies the position of Chairman for Steno Diabetes Center An and Chief Science Officer & Executive Vice President at Novo Nordisk A. Dr. Thomsen is also on the board of BB Biotech AG and Symphogen An and Chairman of the University of Copenhagen. Dr. Thomsen previously held the position of President at The Danish Academy of Technical Sciences. Dr. Thomsen received a doctorate from the University of Copenhagen.
Mads Krogsgaard Thomsen active positions
Companies | Position | Start |
---|---|---|
BB BIOTECH AG | Director/Board Member | 2019-12-31 |
Steno Diabetes Center A/S | Chairman | - |
Novo Nordisk Fonden
Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Chief Executive Officer | 2021-02-28 |
Former positions of Mads Krogsgaard Thomsen
Companies | Position | End |
---|---|---|
NOVO NORDISK A/S | Chief Tech/Sci/R&D Officer | 2021-02-28 |
University of Copenhagen | Chairman | 2018-12-31 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Director/Board Member | - |
The Danish Academy of Technical Sciences | President | - |
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Director/Board Member | - |
Training of Mads Krogsgaard Thomsen
University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BB BIOTECH AG | Finance |
NOVO NORDISK A/S | Health Technology |
Private companies | 4 |
---|---|
Novo Nordisk Fonden
Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Miscellaneous |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Commercial Services |
Steno Diabetes Center A/S |
- Stock Market
- Insiders
- Mads Krogsgaard Thomsen